Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MiNK Therapeutics ( (INKT) ) has issued an announcement.
In response to recent investor inquiries, MiNK Therapeutics clarified that it is in active discussions with multiple parties about potential clinical combination trials involving agenT-797, its proprietary allogeneic iNKT cell therapy. The company is also exploring possible strategic minority investments, underscoring growing external interest in its platform and its applications in critical illness, while emphasizing that no binding agreements for trials or investments have yet been publicly disclosed.
The most recent analyst rating on (INKT) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.
Spark’s Take on INKT Stock
According to Spark, TipRanks’ AI Analyst, INKT is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, negative equity, and highly concerning TTM cash flow metrics). This is partially offset by a constructive earnings call centered on clinical progress and runway, while technicals and valuation provide limited additional support.
To see Spark’s full report on INKT stock, click here.
More about MiNK Therapeutics
MiNK Therapeutics, Inc. is a biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies. Its lead candidate, agenT-797, targets areas of significant unmet medical need, including severe and critical illnesses where novel immunotherapy approaches may offer clinical benefit.
Average Trading Volume: 285,630
Technical Sentiment Signal: Sell
Current Market Cap: $45.2M
Learn more about INKT stock on TipRanks’ Stock Analysis page.